Conjunctivitis Market

Conjunctivitis Market Outlook (2022 to 2032)

The global conjunctivitis market size is expected to be worth USD 1,825.8 Million in 2022. The market is expected to reach USD 3,208.7 Million by 2032, growing at a 5.8% CAGR from 2022 to 2032.

The factors responsible for growth are:

• One of the reasons driving the global market over the projection period is the rising incidence of conjunctivitis in emerging nations.
• Another factor that is likely to drive the global market over the projected period is the rise in the incidence of sexually transmitted diseases (STDs).
• A few risk factors for newborn conjunctivitis include things like unsanitary living situations, early births, and maternal STDs.
• During the projected period, the global conjunctivitis market is anticipated to be constrained by factors such as low illness awareness and inadequate pharmaceutical coverage in developing nations.

Clinical examinations and procedures are carried out to diagnose the condition, which aids medical professionals in making additional decisions about medicine, testing, and recuperation and is expected to accelerate market expansion throughout the projection period.

Report Attribute	Details
Conjunctivitis Market Value (2022)	USD 1825.8 Million
Conjunctivitis Market Anticipated Value (2032)	USD 3208.7 Million
Conjunctivitis Projected Growth Rate (2022 to 2032)	5.8%

Factors Responsible for High Growth Rate in Asia Pacific Conjunctivitis Market

Due to increased awareness, significant increases in healthcare spending, and a rising frequency of ocular allergies in the region, the Asia Pacific conjunctivitis market is anticipated to develop at the highest CAGR during the forecast period. Conjunctivitis is quite prevalent in nations like India. For instance, the state of Tamil Nadu reported a viral conjunctivitis issue among students and workers at schools. Clinical Epidemiology and Global Health, for instance, estimated that 12.22% of Indians suffer from ocular allergies.

The male segment is projected to have a higher prevalence (13.44%) than females (10.71%). During the projected period, these trends are anticipated to support market expansion in the region.

The emergence of cost-effective generic drugs is probably going to severely impede market expansion. Due to an increase in the frequency of infections, poor hygienic conditions in developing nations, and protracted deliveries in several of the region's countries, the Asia Pacific region is anticipated to have the third-largest share. In addition, it is anticipated that the expanding medical tourism sector in nations like Malaysia, China, and India would increase demand for treatment. Over the anticipated time, these factors boost market expansion in the region.

The market share of the other regions, including Latin America, the Middle East, and Africa, was relatively smaller throughout the projection period. According to epidemiological research, for example, the incidence of ocular allergy in Mexico is estimated to be at 16.7%. Particularly noticeable in tropical or warm settings is this high frequency of ocular allergies.

Innovations and Developments to Aid Pharma Companies to Capture Larger Market Share

Pharmaceutical companies are developing new options for treating conjunctivitis while evaluating how well they relieve ocular irritation. Large pharmaceutical companies are funding all of this research. These factors are promoting the expansion of the global market for conjunctivitis treatment.

Due to the increased illness awareness and increased global healthcare spending, the conjunctivitis market is expected to alter over the forecast period, allowing medication producers to extend their share.

Companies and academics are striving to evaluate obstacles and look for possibilities that might have an impact on bacterial conjunctivitis research and development. The focus of the currently being developed therapies is on cutting-edge methods to cure or ameliorate the state of illness. However, it is anticipated that these regions are likely to see development in the future owing to the expanded market presence of well-known brands and the high prevalence of ocular allergies there.

Companies like Sun Pharmaceuticals and Alembic Pharmaceuticals Limited are expanding their market share globally by concentrating on product approvals and the introduction of generic versions of already available medications. Moreover, startups like Ocular Therapeutix, Inc. and Eton Pharmaceutical are also working to secure regulatory clearances for their pipeline candidates, which is anticipated to help them boost their profits during the projection period.

The global market share of conjunctivitis is predicted to rise owing to fast-growing technological advancement, expanding geriatric population, growing disease prevalence, and surging demand for effective drug types. These are all responsible for fueling the growth of the global market of this industry.

Growing Air Pollution A Key Reason for Market Growth

The global conjunctivitis market is motivated by increasing air pollution in the majority of cities across the world. The National Center for Biotechnology Information (NCBI) published a research study in 2016 that the critical reasons for the occurrence and worsening of allergic conjunctivitis are ambient air pollution and weather changes.

This is accredited to the conjunctiva being sensitive to environmental particles coupled with direct contact of the conjunctiva with the external environment. Therefore, an increase in air pollution promotes the growth of the global conjunctivitis treatment market.

Increasing Awareness Results in Market Growth

Increased awareness about allergic conjunctivitis amongst the medical community, patients, and individuals associated with patients is one of the key market-driving factors responsible for the growth of the conjunctivitis market. Developing lifestyles and overall growth in the number of patients suffering from allergic conjunctivitis are primary factors boosting the growth of the market.

Many biopharmaceutical companies plan to invest in research and development initiatives to develop new drugs and therapies for treating ocular disorders. Recently, the increasing awareness of ocular allergies has significantly increased owing to several factors such as faster urbanization and a growing number of allergens.

Nearly 80 million North Americans Suffer from Ocular Allergy

The North American market is anticipated to dominate the global conjunctivitis market share over the forecast period. FMI analysts predict that by 2022, the regional conjunctivitis market will bloom with a revenue share of over 27%.

North America is the biggest market due to the increasing prevalence of allergic conjunctivitis in this region. An estimate says that nearly 70 to 80 million Americans suffer from ocular allergies. There is greater awareness of ophthalmic allergies in the region.

This, coupled with the existence of majority players, which leads to novel and advanced drug launches, and the robust spread of this disease, are factors attributing to the market's growth. A country like the USA has a major presence of positive reimbursement policies, and this is the key reason for this region's dominance in this market.

Why is Europe a Promising Market?

Europe is accountable for a 22% market share in the global conjunctivitis market. The emergence as the second-largest regional market owing to the growing potential patient population in the region along with the growing use of sophisticated drugs. For example, based on the British Journal of Ophthalmology, in the United Kingdom, seasonal allergic conjunctivitis is a widespread and one of the mild forms of allergic conjunctivitis. It accounts for 25 to 50 percent of all ocular allergy cases, and it is predicted to affect between 10 to 15 percent of the population in the United Kingdom.

Start-ups Grazing the Ocular Disorders Market

• In March 2022, Visus Therapeutics Inc., a clinical-stage pharmaceutical company aims on creating an inventive ophthalmic therapy to enhance vision for individuals across the globe. The company announced the launch of the first of two pivotal Phase 3 trials (BRIO-I and BRIO-II) for its lead asset, BRIMOCHOL™ PF, which is a topical preservative-free ophthalmic solution for treating presbyopia.
• In October 2021, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage genome editing company, and SparingVision, a genomic medicine company developing vision-saving treatments for ocular diseases, announced a strategic collaboration to develop innovative genomic medicines using CRISPR/Cas9 technology for treating ocular diseases.

Key Players Benchmarking the Conjunctivitis Market

Some of the key players in the conjunctivitis market are Boehringer Ingelheim GmbH, Allergan Inc., Sanofi-Aventis, Atopix Therapeutics Ltd., Novartis AG, Ocular Therapeutix, Inc., Bausch & Lomb Inc., Akorn Incorporated., Auven Therapeutics, Sirion Therapeutics, Inc., Sun Pharma Advanced Research Company Ltd., C Boehringer Ingelheim International GmbH., IBA Vision Ophthalmics, Pfizer Inc., Merck & Co., Inc., and Santen Pharmaceuticals Co. Ltd.

Who	Bausch & Lomb Inc.
When	May 2022
Strategic Move	Bausch + Lomb Corporation - a leading eye health company launched as a publicly traded company focused on protecting and improving the gift of sight for millions of people around the globe when it started trading under the BLCO symbol on the New York Stock Exchange and Toronto Stock Exchange.

Who	Sanofi-Aventis
When	August 2022
Strategic Move	Sanofi and Innovent Biologics collaborated to bring innovative medicines to patients in China with difficult-to-treat cancers. Both companies are committed to accelerating the development and commercialization of two Sanofi key clinical-stage oncology assets. Moreover, besides the agreement and collaboration, Sanofi will invest €300 million in Innovent through the subscription of novel common shares.

Report Scope

Report Attribute	Details
Growth Rate	CAGR of 5.8% from 2022 to 2032
Base Year for Estimation	2021
Historical Data	2016 to 2021
Forecast Period	2022 to 2032
Quantitative Units	Revenue in USD Million and CAGR from 2022 to 2032
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Type, Treatment, Region
Regions Covered	North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East and Africa
Key Countries Profiled	United States of America, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC Countries, South Africa
Key Companies Profiled	Boehringer Ingelheim GmbH; Allergan Inc.; Sanofi-Aventis; Atopix Therapeutics Ltd.; Novartis AG,Ocular TherapeutixInc.; Bausch & Lomb Inc.; Akorn Incorporated.; Auven Therapeutics; Sirion TherapeuticsInc.; Sun Pharma Advanced Research Company Ltd.; Boehringer Ingelheim International GmbH.; IBA Vision Ophthalmics; Pfizer Inc.; Merck & Co.Inc.; Santen Pharmaceuticals Co. Ltd.
Customization	Available Upon Request

Key Segments of the Conjunctivitis Market

By Type:

• Giant Papillary Conjunctivitis
• Seasonal Allergic Conjunctivitis
• Vernal Keratoconjunctivitis
• Contact Conjunctivitis
• Perennial Conjunctivitis
• Atopic Keratoconjunctivitis

By Treatment:

• Mast Cell Stabilizers
• Decongestant
• Immunotherapy
• Antihistamines
• Non-steroidal Anti-Inflammatory Drugs
• Olopatadine
• Epinastine
• Ointments
• Others

By Region:

• North America
• Latin America
• Asia Pacific
• Middle East and Africa
• Europe

Frequently Asked Questions

What is the Growth Outlook for the Conjunctivitis Market?

The growth outlook for the conjunctivitis market is predicted to advance at a CAGR of 5.8% from 2022 to 2032.

Which Region Leads the Conjunctivitis Market?

The North American region is anticipated to lead the conjunctivitis market during the forecast period.

How much Growth Potential does the Conjunctivitis Market hold?

The conjunctivitis market is likely to hold a valuation of USD 3208.7 million by 2032.